Physician profile
Pavan Ahuja
NPI 1578566675
$26,202.09
in general payments reported to CMS, 2019-2025
61 companies · $3,525 in 2025
The $3,525 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,627 · 2020: $2,307 · 2021: $3,837 · 2022: $3,782 · 2023: $4,522 · 2024: $4,603 · 2025: $3,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,630.95 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,569.86 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $2,458.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,984.72 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $1,833.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,595.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $1,564.55 | 2020-2024 | Nexletol |
| Insulet Corporation | $1,342.41 | 2019-2025 | Omnipod |
| Abbvie INC. | $1,338.91 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Merck Sharp & Dohme LLC | $1,301.83 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $1,116.67 | 2021-2025 | |
| Abbott Laboratories | $1,084.64 | 2019-2025 | Freestyle Libre 3, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $842.24 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $784.26 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $488.93 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Janssen Pharmaceuticals, INC | $456.76 | 2019-2024 | Xarelto |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $373.03 | 2019-2024 | |
| Mylan Specialty L.P. | $344.97 | 2019-2024 | Yupelri |
| Sumitomo Pharma America, INC. | $324.91 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $297.76 | 2019-2023 | Veozah, Myrbetriq |
| Dexcom, INC. | $297.72 | 2019-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.29 | 2019-2024 | Xifaxan |
| Allergan, INC. | $247.60 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $239.99 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $217.63 | 2019-2025 | Unithroid |
| Viatris Specialty LLC | $200.47 | 2025 | Yupelri |
| Amarin Pharma, INC. | $181.54 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $166.77 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $162.35 | 2022 | |
| Ibsa Pharma INC. | $159.38 | 2020-2024 | Tirosint, Licart |
| Lundbeck LLC | $158.60 | 2023-2025 | Vyepti, Rexulti |
| Radius Health, INC. | $158.49 | 2019-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $148.70 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $135.68 | 2023-2024 | Rexulti |
| Cequr Corporation | $127.54 | 2024-2025 | Cequr Simplicity |
| Biohaven Pharmaceuticals, INC. | $118.28 | 2021 | |
| Beta Bionics, INC. | $113.72 | 2024 | Ilet Bionic Pancreas |
| Tandem Diabetes Care, INC. | $108.87 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $72.66 | 2023 | Signifor Lar, Isturisa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.14 | 2023-2025 | Caplyta |
| Antares Pharma, INC. | $63.06 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Exact Sciences Corporation | $60.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shire North American Group INC | $54.50 | 2019 | |
| Grifols USA, LLC | $54.26 | 2019 | |
| Eisai INC. | $51.06 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $47.79 | 2025 | |
| Medtronic, INC. | $42.89 | 2023-2024 | Intellis Adaptivestim |
| Vanda Pharmaceuticals INC. | $36.74 | 2025 | Fanapt |
| Lifescan, INC. | $36.63 | 2020 | |
| Nevro Corp. | $35.38 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $34.41 | 2019-2021 | |
| Zyla Life Sciences, INC. | $31.69 | 2019 | |
| Alexion Pharmaceuticals, INC. | $28.91 | 2022 | |
| Amryt Pharma Holdings LTD | $28.24 | 2021-2023 | Mycapssa |
| Ultragenyx Pharmaceutical INC. | $25.88 | 2023 | |
| Biocryst US Sales Co., LLC | $24.24 | 2022 | |
| Boston Scientific Corporation | $20.62 | 2024 | Watchman Flx |
| Phathom Pharmaceuticals, INC. | $19.61 | 2024 | Voquezna |
| Optos, INC. | $19.60 | 2021 | |
| Puma Biotechnology, INC. | $17.75 | 2019 | |
| Ethicon INC. | $15.97 | 2025 | Monarch Platform |
| Medtronic Minimed, INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Ahuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.